Yahoo Web Search

Search results

    • IRLAB publishes Annual Report for 2023

      Digital Journal· 2 days ago

      Pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson's disease. In addition, the company ...

    • IRLAB publishes Annual Report for 2023

      Morningstar· 2 days ago

      GOTHENBURG, SWEDEN / ACCESSWIRE / April 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson'